⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Postoperative Morbidity and Mortality After Gastric Cancer Surgery

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Postoperative Morbidity and Mortality After Gastric Cancer Surgery

Official Title: 90-day Postoperative Morbidity and Mortality After Elective Surgery for Gastric Cancer

Study ID: NCT06277908

Study Description

Brief Summary: Gastric cancer is still one of the main health care issue and gastrectomy with lymph node dissection is the only chance to be cure. Trials show that the postoperative course differs significantly between eastern and western centers, as well as between clinics within Russian Federation. Postoperative 30-day postoperative mortality after gastric cancer surgery ranges from 1% to 5%, and postoperative complication rates range from 10% to 40%. To improve the quality of further studies and recommendations for standardization of surgical treatment of gastric cancer and its complications, there is a need to study the differences in 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation.

Detailed Description: According to 2018 World Health Organization (WHO) data, gastric cancer is the fourth most common malignant disease and the third leading cause of cancer-related deaths worldwide. Surgery with lymphadenectomy remains the standard of care. Despite significant changes in gastric cancer treatment protocols, surgery is still associated with high risks of complications, with rates varying from clinic to clinic. And currently, the use of multimodal treatments and standardization of surgical procedures are proposed as strategies to improve outcomes. In addition, the use of laparoscopic and robotic techniques have been proposed to provide better short-term results compared to open surgery and comparable long-term oncological outcomes. Randomized trials show that the postoperative course differs significantly between eastern and western centers, as well as between clinics within Russian Federation. Postoperative 30-day postoperative mortality after gastric cancer surgery ranges from 1% to 5%, and postoperative complication rates range from 10% to 40%. While mortality is easier to quantify, there are no standardized criteria for calculating postoperative complication rates. To improve the quality of further studies and recommendations for standardization of surgical treatment of gastric cancer and its complications, there is a need to study the differences in 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

A.S. Loginov Moscow Clinical Scientific Center, Moscow, , Russian Federation

A.Tsyb Medical Radiological Research Centre, Moscow, , Russian Federation

I.M. Sechenov First Moscow State Medical University, Moscow, , Russian Federation

P.Herzen Moscow Oncological Research Institute, Moscow, , Russian Federation

Petrovsky National Research Centre of Surgery, Moscow, , Russian Federation

Vishnevsky National Medical Research Center of Surgery, Moscow, , Russian Federation

Nizhny Novgorod Regional Clinical Oncological Dispensary, Nizhny Novgorod, , Russian Federation

National Medical Research Centre for Oncology, Rostov-on-Don, , Russian Federation

Petrov National Medical Research Center of Oncology, Saint Petersburg, , Russian Federation

Contact Details

Name: Andrey Ryabov, MD, PhD

Affiliation: P.Herzen Moscow Oncological Research Institute

Role: STUDY_DIRECTOR

Name: Vladimir Khomyakov, MD, PhD

Affiliation: P.Herzen Moscow Oncological Research Institute

Role: PRINCIPAL_INVESTIGATOR

Name: Nuriddin Abdulkhakimov, MD, PhD

Affiliation: P.Herzen Moscow Oncological Research Institute

Role: PRINCIPAL_INVESTIGATOR

Name: Pavel Smirnov

Affiliation: P.Herzen Moscow Oncological Research Institute

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: